Physician profile
Mark S Puricelli
NPI 1760596514
$45,167.97
in general payments reported to CMS, 2019-2025
32 companies · $651 in 2025
The $651 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20K · 2020: $3,901 · 2021: $1,648 · 2022: $467 · 2023: $11K · 2024: $7,060 · 2025: $651.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $16K · Food and Beverage: $2,759.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16,050.00 |
| Food and Beverage | $2,758.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $20,819.61 | 2019-2021 | |
| Abbvie INC. | $18,054.13 | 2019-2025 | |
| Allergan, INC. | $3,598.27 | 2019-2022 | |
| Lundbeck LLC | $604.03 | 2021-2025 | Vyepti |
| Teva Pharmaceuticals USA, INC. | $234.65 | 2019-2025 | Austedo Xr, Austedo Xr |
| Biogen, INC. | $221.90 | 2019-2025 | Vumerity, Tysabri |
| Tg Therapeutics, INC. | $200.30 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $190.36 | 2019 | |
| Genzyme Corporation | $167.87 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $156.35 | 2019-2020 | |
| Pfizer INC. | $155.88 | 2019-2025 | |
| Vanda Pharmaceuticals INC. | $105.23 | 2024 | Ponvory |
| Ucb, INC. | $97.78 | 2019-2020 | |
| Emd Serono, INC. | $79.17 | 2019 | |
| Lilly USA, LLC | $61.28 | 2019-2025 | Kisunla |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $59.91 | 2019 | |
| Acorda Therapeutics, INC | $49.07 | 2019 | |
| Sunovion Pharmaceuticals INC. | $36.96 | 2019 | |
| Csl Behring | $31.77 | 2025 | Hizentra |
| Adamas Pharmaceuticals, INC. | $29.34 | 2019 | |
| Ge Healthcare | $29.26 | 2019 | |
| Genentech USA, INC. | $21.90 | 2024 | Ocrevus Zunovo, Ocrevus |
| Argenx US, INC. | $21.32 | 2025 | Vyvgart, Vyvgart Hytrulo |
| Alexion Pharmaceuticals, INC. | $20.55 | 2025 | Ultomiris |
| Vertical Pharmaceuticals, LLC | $17.95 | 2019 | |
| Tanabe Pharma America, INC. | $16.80 | 2019 | |
| Kyowa Kirin, INC. | $15.96 | 2020 | |
| Medtronic USA, INC. | $15.62 | 2019 | |
| Jazz Pharmaceuticals INC. | $14.50 | 2019 | |
| Celgene Corporation | $14.08 | 2025 | Zeposia |
| Alnylam Pharmaceuticals INC. | $13.84 | 2019 | |
| Promius Pharma LLC | $12.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Puricelli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.